These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28993335)

  • 1. Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.
    Serrano-Villar S; Caruana G; Zlotnik A; Pérez-Molina JA; Moreno S
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
    Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
    J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
    Sierra-Madero J; Di Perri G; Wood R; Saag M; Frank I; Craig C; Burnside R; McCracken J; Pontani D; Goodrich J; Heera J; Mayer H
    HIV Clin Trials; 2010; 11(3):125-32. PubMed ID: 20736149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
    Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
    AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
    Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679. PubMed ID: 19694034
    [No Abstract]   [Full Text] [Related]  

  • 8. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
    Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
    McGovern RA; Thielen A; Portsmouth S; Mo T; Dong W; Woods CK; Zhong X; Brumme CJ; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):279-86. PubMed ID: 23095934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial.
    Blanco JR; Alejos B; Moreno S
    Clin Microbiol Infect; 2018 Aug; 24(8):900-907. PubMed ID: 29183782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
    Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
    Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.
    Rusconi S; Vitiello P; Adorni F; Colella E; Focà E; Capetti A; Meraviglia P; Abeli C; Bonora S; D'Annunzio M; Di Biagio A; Di Pietro M; Butini L; Orofino G; Colafigli M; d'Ettorre G; Francisci D; Parruti G; Soria A; Buonomini AR; Tommasi C; Mosti S; Bai F; Di Nardo Stuppino S; Morosi M; Montano M; Tau P; Merlini E; Marchetti G
    PLoS One; 2013; 8(11):e80157. PubMed ID: 24244635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.